+ Employee Stock Options Plan
More information about location
Accelerating drug time-to-market
Open for applications
Accelerating drug time-to-market
1-20 employees
Open for applications
+ Employee Stock Options Plan
More information about location
1-20 employees
To empower researchers and regulators to analyse and monitor studies transparently in real-time, leading to improved and safer therapies for devastating diseases.
Drug development times are painfully long, with patients waiting years upon years for new medicines to hit the market. Verisian is hoping to change this, with a range of tools to facilitate faster drug trialling and analysis of results.
The company's products target know pain-points in the clinical trial pipeline. For example, Verisian Builder allows trials to be designed faster by supplying a library of pre-approved modules based on existing studies. Trials can be pooled for analysis with Verisian Pooler, while data can be extracted and virtualized with Verisian Tracer.
Through this suite of offerings, Verisian hopes to streamline clinical trials while maintaining their integrity, speeding up the time-to-market for new drugs. Fresh funding will be used to grow its engineering team as it creates the first version of its "Builder" product, as well as establish and grow its initial design partnerships with tier-1 pharmaceuticals.
Kirsty
Company Specialist at Welcome to the Jungle
Sep 2023
$1.3m
SEED
Westminster, London, UK
Tomás Sabat
(CEO)Was on the Founding Team at Vaticle, where they spent 6 years as COO. Obtained an MPhil from the University of Cambridge.
Henning Kuich
(CTO)Earned a PhD in Systems Biology from Freie Universität Berlin. Spent 7 years at Bayer Pharmaceuticals, ultimately as Senior Computational Scientist.
Share this job
View 2 more jobs at Verisian